Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
Nkarta boosts what it can raise from IPO to up to $221 million
10:27am, Thursday, 09'th Jul 2020
Nkarta Inc. increased the number of shares it will sell in its initial public offering, and the expected pricing also rose, to boost what the San Franciso-based biopharmaceutical company could raise
The biotech sector as a safe bet for investments during the crisis
02:00pm, Monday, 29'th Jun 2020
Biotechnology companies have many growth levers and are to be favored for their defensive qualities, in the context of the health and economic crisis.
The Reopening Killed The V-Shaped Recovery
07:43am, Monday, 29'th Jun 2020
This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19
08:51pm, Sunday, 28'th Jun 2020
GERM offers investors exposure to established providers and ‘unsung heroes’ of biotech and life sciences Continue reading...
Second COVID Wave? Analysis And Updated Investment Strategy
04:11pm, Sunday, 28'th Jun 2020
An imminent second COVID wave remains a serious threat, but it may be fully priced in by now. There are both bad and good things happening, but what I see is th
Analysts Underestimate Gilead COVID-19 Treatment
12:35pm, Friday, 26'th Jun 2020
Sell-side analysts are not giving Gilead a lot of credit for remdesivir. COVID-19 continues to spread and it is increasingly likely to become endemic. Gilead is
Health Care Up On Biotech Demand -- Health Care Roundup | MarketScreener
09:25pm, Thursday, 25'th Jun 2020Health Care Down, But Not By Much, Amid Defensive Bias -- Health Care Roundup
09:02pm, Wednesday, 24'th Jun 2020Healthcare Dashboard For June
11:15am, Wednesday, 24'th Jun 2020
A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages. The best and the worst industri
2 Biotech Stocks With Major Incoming Catalysts | The Motley Fool
10:49am, Wednesday, 24'th Jun 2020
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity
09:48am, Wednesday, 24'th Jun 2020
Xpovio is anticipated to become a blockbuster multiple myeloma MM treatment, and real-world data demonstrate strong market uptake thus far. 2Q sales should exce
The Best Stocks To Buy On Down Days
07:12am, Sunday, 21'st Jun 2020
Risk/reward shifts back to neutral, suggesting volatility will continue through the end of the quarter. Healthcare and technology are top sectors to buy on sale
Here’s why the FDA may approve a Covid-19 vaccine before the November elections, according to Jefferies’ biotech-research team
10:08am, Friday, 19'th Jun 2020
If true, any approval may not actually benefit a vaccine company, but instead other parts of the stock market.
Biogen and Moderna shares show how biotech ETFs may look similar but act differently
07:14pm, Thursday, 18'th Jun 2020
Big shares of a losing biotech stock didn’t stop a pair of four-star-rated ETFs from moving higher Thursday. They may sound similar, but hold distinct investments once you look under the hood.
There's Limited Downside Because The Pros Have FoMo, So Let's Look At Some Stocks
06:59pm, Thursday, 18'th Jun 2020
It's not the Robinhood Crowd that's keeping the stock market indexes lofty. It's the pros that are on the outside looking in. Therefore you are seeing them step
